MENU
+Compare
ESLA
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$0.91
Change
-$0.04 (-4.21%)
Capitalization
32.91M

ESLA Estrella Immunopharma Forecast, Technical & Fundamental Analysis

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors... Show more

ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ESLA with price predictions
Jul 25, 2025

ESLA in +8.64% Uptrend, growing for three consecutive days on July 24, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ESLA advanced for three days, in of 95 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 22, 2025. You may want to consider a long position or call options on ESLA as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ESLA just turned positive on July 22, 2025. Looking at past instances where ESLA's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

ESLA moved below its 50-day moving average on July 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ESLA crossed bearishly below the 50-day moving average on June 20, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ESLA broke above its upper Bollinger Band on July 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ESLA entered a downward trend on July 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ESLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ESLA's P/B Ratio (243.902) is slightly higher than the industry average of (18.028). P/E Ratio (0.000) is within average values for comparable stocks, (59.593). ESLA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.512). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (278.844).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
5858 Horton Street
Phone
+1 510 318-9098
Employees
N/A
Web
https://www.estrellabio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RVPH0.470.04
+9.63%
Reviva Pharmaceuticals Holdings
KOP34.591.10
+3.28%
Koppers Holdings
NWGL1.050.02
+1.94%
Nature Wood Group Limited
AXSM104.97N/A
N/A
Axsome Therapeutics
ORLY97.66-0.50
-0.51%
O'Reilly Automotive Inc

ESLA and Stocks

Correlation & Price change

A.I.dvisor tells us that ESLA and CARM have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and CARM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESLA
1D Price
Change %
ESLA100%
-4.16%
CARM - ESLA
25%
Poorly correlated
-1.62%
FATE - ESLA
23%
Poorly correlated
-0.80%
CMND - ESLA
23%
Poorly correlated
N/A
IONS - ESLA
22%
Poorly correlated
N/A
PSTV - ESLA
22%
Poorly correlated
-11.18%
More